Beyond AChR: Recognizing and Treating MuSK Ab+, LRP4 Ab+ and Triple Seronegative Myasthenia Gravis
Start date: Sept 1, 2026
End date: Sept 1, 2027
Estimated time to complete: 0.75 hours
Credits: 0.75 AMA PRA Category 1 Credits™
Jointly Provided by
This program is supported by educational grants from argenx.
This accredited CME program examines best practices to diagnose and treat patients with ultra-rare forms of myasthenia gravis.
The most prevalent form of myasthenia gravis is associated with antibodies against the acetylcholine receptor (AChR Ab+). However, 15- 20% of patients with myasthenia gravis are not AChR Ab+. These clinically important and underrecognized subsets of patients harbor antibodies against muscle-specific kinase (MuSK Ab+) lipoprotein receptor-related protein 4 (LRP4 Ab+), or test negative for all known antibodies (triple seronegative MG). These patients present unique diagnostic and treatment challenges that necessitate expert guidance to improve their management.
Led by Drs. Neelam Goyal and Christyn Edmundson, this activity uses case studies involving three different patients suspected of having MuSK Ab+, LRP4 Ab+, and Triple Seronegative Myasthenia Gravis to discuss how they assess those patients, ensure proper diagnosis, and decide which treatment option is most appropriate for the individual patient.
Target Audience
This activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology, rheumatology, and family practice. Other members of the care team may also participate.
Learning Objectives
After participating in the activity, learners should be better able to:
- Describe the current hypotheses regarding disease mechanisms in MuSK Ab+, LRP4 Ab+, and triple seronegative MG and apply this mechanistic understanding to diagnostic reasoning and treatment planning.
- Recognize the subtype-specific clinical features of MuSK Ab+, LRP4 Ab+, and triple seronegative MG and apply an appropriate diagnostic workup.
- Identify patients with MuSK Ab+, LRP4 Ab+, or triple seronegative MG who are suboptimally controlled on traditional therapies and apply subtype-specific evidence to guide timely transition to newer therapies.
- Articulate the distinct treatment burden and disease progression patterns in MuSK+, LRP4+, and triple seronegative MG and apply treatment goals that reflect the potential benefits of targeted over traditional therapy.
Activity Faculty
Neelam Goyal, MD
Clinical Professor, Neuromuscular Medicine
Stanford University
Stanford, CA
Christyn Edmundson, MD
Neurologist
Swedish Neuroscience Institute
Seattle, WA
Disclosure Statement
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.
Disclosure of relevant financial relationships are as follows:
Faculty Educator/Planner
Dr. Goyal discloses the following relevant financial relationships with ineligible companies:
- Advisory Board/Consultant: argenx, Alexion, UCB, Janssen, Amgen, Novartis, Immunovant*, Dianthus, Seismic*, Cartesian*, EMD Serono*
- Research Grant: argenx
Dr. Edmunson discloses the following relevant financial relationships with ineligible companies:
- Advisory Board/Consultant: Alnylam, Alexion, Amgen, argenx, Kyverna, UCB
- Speaker’s Bureau: Alnylam, Alexion, Amgen, argenx, UCB
*Relationship has ended
Academy and CheckRare CE planners and reviewers for this activity have no relevant financial relationships with any ineligible companies.
This activity will review off-label or investigational information.
The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.
Accreditation and Credit Designation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
American Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other HCPs
Other members of the care team will receive a certificate of participation.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.
Privacy
For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm For more information about CheckRare’s privacy policy, please access https://checkrare.com/privacy/
Contact
For any questions, please contact: [email protected]
Copyright
© 2026. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
